Phage therapy of pulmonary infections

Bacteriophage

Volumn 5, Issue 1, 2015, Pages

  Abedon, Stephen T ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Lung infection; Phage therapy; Pharmacology; Pleural infection; Pulmonary infection

Indexed keywords

ANTIBIOTIC AGENT;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; BACTERIOPHAGE; BRONCHOPNEUMONIA; CHRONIC BRONCHITIS; COLONY FORMING UNIT; HUMAN; LUNG ABSCESS; LUNG INFECTION; NONHUMAN; PHAGE THERAPY; PLEURECTOMY; REVIEW; THORACOPLASTY;

EID: 85019668348     PISSN: 21597073     EISSN: 21597081     Source Type: Journal    
DOI: 10.1080/21597081.2015.1020260     Document Type: Review

References (71)

1. Harper DR. Biological control by microorganisms. The Encyclopedia of Life Sciences. Chichester, England, UK: John Wiley & Sons, 2006:1-10.
2. Abedon ST. Kinetics of phage-mediated biocontrol of bacteria. Foodborne Pathog Dis 2009; 6:807-15; PMID:19459758; http://dx.doi.org/10.1089/fpd. 2008.0242
3. Chanishvili N. Phage therapy—history from Twort and d’Herelle through Soviet experience to current approaches. Adv Virus Res 2012; 83:3-40; PMID:22748807; http://dx.doi.org/10.1016/B978-0-12-394438-2.00001-3
4. Summers WC. History of phage research and phage therapy. In: Waldor M, Friedman D, Adhya S, eds. Phages: Their Role in Bacterial Pathogenesis and Biotechnology. Washington DC: ASM Press, 2005
5. Kutter E, De Vos D, Gvaxalia G, Alavidze Z, Gogokhia L, Kuhl S, Abedon ST. Phage therapy in clinical practice: treatment of human infections. Curr Pharm Biotechnol 2010; 11:69-86; PMID:20214609; http://dx. doi.org/10.2174/138920110790725401
6. Abedon ST, Kuhl SJ, Blasdel BG, Kutter EM. Phage treatment of human infections. Bacteriophage 2011; 1:66-85; PMID:22334863; http://dx.doi.org/10.4161/bact.1.2.15845
7. Allen HK, Trachsel J, Looft T, Casey TA. Finding alternatives to antibiotics. Ann N Y Acad Sci 2014; 1323:91-100; PMID:24953233; http://dx.doi.org/10.1111/nyas.12468
8. Baquero F, Coque TM, Canton R. Counteracting antibiotic resistance: breaking barriers among antibacterial strategies. Expert Opin Ther Targets 2014; 18:851-61; PMID:24881465; http://dx.doi.org/10.1517/14728222.2014.925881]
9. Hoeflmayr J. Inhalationstherapie mit Bakteriophagen bei therapieresistenten Infektionen [Inhalation therapy with bacteriophages for treatment-resistant infections]. In: Nückel H, ed. Fortschritte der biologischen Aerosol-Forschung in den Jahren 1957-1961 [Advances in Biological Aerosols Research in the Years 1957-1961]. Stuttgart, Germany: 1962:403-9.
10. Krestovikova VA. Phage therapy and phage prophylaxis and their development through the work of Soviet researchers. Zh Mikrobiol Epidemiol Immunobiol 1947; 3:56-65
11. Slopek S, Durlakova I, Weber-Dabrowska B, Kucharewicz-Krukowska A, Dabrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. II. Detailed evalulation of the results. Arch Immunol Ther Exp 1983; 31:293-327; PMID:6651485
12. Hoe S, Semler DD, Goudie AD, Lynch KH, Matinkhoo S, Finlay WH, Dennis JJ, Vehring R. Respirable bacteriophages for the treatment of bacterial lung infections. J Aerosol Med Pulm Drug Deliv 2013; 26:317-35; PMID:23597003; http://dx.doi.org/10.1089/jamp.2012.1001
13. Hoe S, Boraey MA, Ivey JW, Finlay WH, Vehring R. Manufacturing and device options for the delivery of biotherapeutics. J Aerosol Med Pulm Drug Deliv 2014; 27:315-28; PMID:24299502; http://dx.doi.org/10.1089/jamp.2013.1090
14. El-Gohary FA, Huff WE, Huff GR, Rath NC, Zhou ZY, Donoghue AM. Environmental augmentation with bacteriophage prevents colibacillosis in broiler chickens. Poult Sci 2014; 93:2788-92; PMID:25214555; http://dx.doi.org/10.3382/ps.2014-04282
15. Tsonos J, Vandenheuvel D, Briers Y, De GH, Hernalsteens JP, Lavigne R. Hurdles in bacteriophage therapy: deconstructing the parameters. Vet Microbiol 2014; 171:460-9; PMID:24315040; http://dx.doi.org/10.1016/j.vetmic.2013.11.001
16. Abedon ST, Thomas-Abedon C. Phage therapy pharmacology. Curr Pharm Biotechnol 2010; 11:28-47; PMID:20214606; http://dx.doi.org/10.2174/138920-110790725410
17. Abedon S. Phage therapy pharmacology: calculating phage dosing. Adv Appl Microbiol 2011; 77:1-40; PMID:22050820; http://dx.doi.org/10.1016/B978-0-12-387044-5.00001-7
18. Ryan EM, Gorman SP, Donnelly RF, Gilmore BF. Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. Journal of Pharmacy and Pharamcology 2011; 63:1253-64; PMID:21899540; http://dx.doi.org/10.1111/j.2042-7158.2011.01324.x
19. Abedon ST. Phage therapy best practices. In: Hyman P, Abedon ST, eds. Bacteriophages in Health and Disease. Wallingford, UK: CABI Press, 2012:256-72.
20. Abedon ST. Bacteriophages as drugs: the pharmacology of phage therapy. In: Borysowski J, Miedzybrodzki R, Górski A, eds. Phage Therapy: Current Research and Applications. Norfolk, UK: Caister Academic Press, 2014:69-100.
21. Abedon ST. Phage therapy: eco-physiological pharmacology. Scientifica 2014; 2014:581639; PMID:25031881; http://dx.doi.org/10.1155/2014/581639
22. Pouillot F, Chomton M, Blois H, Courroux C, Noelig J, Bidet P, Bingen E, Bonacorsi S. Efficacy of bacteriophage therapy in experimental sepsis and meningitis caused by a clone O25b:H4-ST131 Escherichia coli strain producing CTX-M-15. Antimicrob Agents Chemother 2012; 56:3568-75; PMID:22491690; http://dx.doi.org/10.1128/AAC.06330-11
23. Takemura-Uchiyama I, Uchiyama J, Osanai M, Morimoto N, Asagiri T, Ujihara T, Daibata M, Sugiura T, Matsuzaki S. Experimental phage therapy against lethal lung-derived septicemia caused by Staphylococcus aureus in mice. Microbes Infect 2014; 16:512-7; PMID:24631574; http://dx.doi.org/10.1016/j.micinf. 2014.02.011
24. Misra A, Hickey AJ, Rossi C, Borchard G, Terada H, Makino K, Fourie PB, Colombo P. Inhaled drug therapy for treatment of tuberculosis. Tuberculosis (Edinb) 2011; 91:71-81; PMID:20875771; http://dx.doi.org/10.1016/j.tube.2010.08.009
25. Gupta A, Pandya SM, Mohammad I, Agrawal AK, Mohan M, Misra A. Particulate pulmonary delivery systems containing anti-tuberculosis agents. Crit Rev Ther Drug Carrier Syst 2013; 30:277-91; PMID:23662603; http://dx.doi.org/10.1615/CritRevTherDrugCarrierSyst.2013005684
26. Morrison S, Gardner RE. The treatment of a lung abscess due to Bacillus coli with a lytic filtrate. J Am Med Assoc 1936; 107:33-4;’ http://dx.doi.org/10.1001/jama.1936.92770270005010c
27. A Literature Review of the Practical Application of Bacteriophage Research. Hauppauge, New York: Nova Publishers, 2012.
28. Shishenko SF. To the issue of application of D’Herelle’s bacteriophage in children surgery. Select Art Azerbaijan Inst Micro Epidem 1938; 6:107-14
29. Cevey M, Schwiez Z. Le bactériophage dans le traitement des empyémes pleuraux à germes résistants aux antibiotiques [Bacteriophage in the treatment of pleural empyema antibiotic resistant bacteria]. Tuberk (Swiss Tuberculosis Journal or Schw Zt Tbc) 1958;; 15:34-9
30. Kutter EM. Bacteriophage therapy: past and present. In: Schaecter M, ed. Encyclopedia of Microbiology. Oxford: Elsevier, 2009:258-66.
31. Pirnay JP, De VD, Verbeken G, Merabishvili M, Chanishvili N, Vaneechoutte M, Zizi M, Laire G, Lavigne R, Huys I, et al. The phage therapy paradigm: pr^et-à-porter or sur-mesure? Pharm Res 2011; 28:934-7; PMID:21063753; http://dx.doi.org/10.1007/s11095-010-0313-5
32. Kvachadze L, Balarjishvili N, Meskhi T, Tevdoradze E, Skhirtladze N, Pataridze T, Adamia R, Topuria T, Kutter E, Rohde C, et al. Evaluation of lytic activity of staphylococcal bacteriophage Sb-1 against freshly isolated clinical pathogens. Microb Biotechnol 2011; 4:643-50; PMID:21481199; http://dx.doi.org/10.1111/j.1751-7915.2011.00259.x
33. Delacoste P. Considérations sur le traitement des affections respiratoires banales au moyen de bactériophages [Considerations on the treatment of common respiratory diseases by means of bacteriophages]. Rev Med Suisse Romande 1959; 79:552-63; PMID:13815551
34. Garsevanishvili TI. [Certain methodological aspects of the use of inhalation of a polyvalent bacteriophage in the treatment of pneumonia of young children]. Pediat-Zhurnal G N Speranskogo 1974; 53;65-6; PMID:4276158
35. Nikolaeva Y. Staphylococcal bacteriophage and its application in clinic. Selected Articles of the Jubilee Symposium Dedicated to the 50th Anniversary of the Tbilisi Institute of Vaccine and Sera. 1974;364-6
36. Sakandelidze VM, Meipariani AN. Use of combined phages in suppurative-inflammatory diseases. ZhMikrobiol Epidemiol Immunobiol 1974; 6:135-6; PMID:4411424
37. Sulakvelidze A, Alavidze, Z, Morris, JG, Jr. Bacteriophage therapy. Antimicrob Agents Chemother 2001; 45:649-59; PMID:11181338; http://dx.doi.org/10.1128/AAC.45.3.649-659.2001
38. Ioseliani GD, Meladze GD, Chkhetiia NS, Mebuke MG, Kiknadze NI. Use of bacteriophage with antibiotics for prevention of acute postresectional pleural empyemas in chronic pulmonary suppurations]. Grudnaia Khirurgiia 1980; 6:63-7; PMID:6450089
39. Sulakvelidze A, Kutter E. Bacteriophage therapy in humans. In: Kutter E, Sulakvelidze A, eds. Bacteriophages: Biology and Application. Boca Raton, Florida: CRC Press, 2005:381-436.
40. Meladze GD, Mebuke MG, Chkhetia NS, Kiknadze NI, Koguashvili GG, Timoshuk II, Larionova NG, Vasadze GK. Efficacy of staphylococcal bacteriophage in treatment of purulent diseases of lungs and pleura]. Grudnaia Khirurgiia 1982; 1:53-6
41. Chkhetia NS. Treatment of lung disease. 1984. Dissertation, Tbilisi, Georgia.
42. Ślopek S, Weber-Dąbrowska B, Dąbrowski M, Kucharewicz-Krukowska A. Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp 1987; 35:569-83; PMID:3455647
43. Ślopek S, Durlakova I, Weber-Dąbrowska B, Kucharewicz-Krukowska A, Dąbrowski M, Bisikiewicz R. Results of bacteriophage treatment of suppurative bacterial infections. I. General evaluation of the results. Arch Immunol Ther Exp 1983; 31:267-91; PMID:6651484
44. Ślopek S, Kucharewicz-Krukowska A, Weber-Dąbrowska B, Dąbrowski M. Results of bacteriophage treatment of suppurative bacterial infections. VI. Analysis of treatment of suppurative staphylococcal infections. Arch Immunol Ther Exp 1985; 33:261-73; PMID:2935117
45. Ślopek S, Kucharewicz-Krukowska A, Weber-Dąbrowska B, Dąbrowski M. Results of bacteriophage treatment of suppurative bacterial infections. V. Evaluation of the results obtained in children. Archivum Immunologiae et Therapiae Experimentalis 1985; 33:241-59; PMID:2935116
46. Ślopek S, Kucharewicz-Krukowska A, Weber-Dąbrowska B, Dąbrowski M. Results of bacteriophage treatment of suppurative bacterial infections. IV. Evaluation of results obtained in 370 cases. Arch Immunol Ther Exp 1985; 33:219-40; PMID:2935115
47. Weber-Dąbrowska B, Mulczyk M, Górski A. Bacteriophage therapy of bacterial infections: An update of our institute’s experience. Arch Immunol Ther Exp 2000; 48:547-51; PMID:11197610
48. Kutateladze M, Adamia R. Phage therapy experience at the Eliava Institute. Med Mal Infect 2008; 38:426-30; PMID:18687542; http://dx.doi.org/10.1016/j. medmal.2008.06.023
49. Chan BK, Abedon ST. Phage therapy pharmacology: phage cocktails. Adv Appl Microbiol 2012; 78:1-23; PMID:22305091; http://dx.doi.org/10.1016/B978-0-12-394805-2.00001-4
50. Chan BK, Abedon ST, Loc-Carrillo C. Phage cocktails and the future of phage therapy. Future Microbiol 2013; 8:769-83; PMID:23701332; http://dx.doi.org/10.2217/fmb.13.47
51. Saussereau E, Vachier I, Chiron R, Godbert B, Sermet I, Dufour N, Pirnay JP, De Vos D, Carrié F, Molinari N, et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect 2014; 20:O983-O990; PMID:24920209; http://dx.doi.org/10.1111/1469-0691.12712
52. James CE, Davies EV, Fothergill JL, Walshaw MJ, Beale CM, Brockhurst MA, Winstanley C. Lytic activity by temperate phages of Pseudomonas aeruginosa in long-term cystic fibrosis chronic lung infections. ISME J 2014; PMID:25461970
53. Friman VP, Ghoul M, Molin S, Johansen HK, Buckling A. Pseudomonas aeruginosa adaptation to lungs of cystic fibrosis patients leads to lowered resistance to phage and protist enemies. PLoS One 2013; 8:e75380; PMID:24069407; http://dx.doi.org/10.1371/journal. pone.0075380
54. Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, LiPuma JJ. Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis 1-15-2010; 201:264-71; PMID:20001604; http://dx.doi.org/10.1086/649227
55. Debarbieux L, Leduc D, Maura D, Morello E, Criscuolo A, Grossi O, Balloy V, Touqui L. Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J Infect Dis 4-1-2010; 201:1096-104; PMID:20196657; http://dx.doi.org/10.1086/651135
56. Morello E, Saussereau E, Maura D, Huerre M, Touqui L, Debarbieux L. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 2011; 6: e16963; PMID:21347240; http://dx.doi.org/10.1371/journal.pone.0016963
57. Alemayehu D, Casey PG, McAuliffe O, Guinane CM, Martin JG, Shanahan F, Coffey A, Ross RP, Hill C. Bacteriophages fMR299-2 and fNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 2012; 3:e00029-12; PMID:22396480; http://dx.doi.org/10.1128/mBio.00029-12
58. Henry M, Lavigne R, Debarbieux L. Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob Agents Chemother 2013; 57:5961-8; PMID:24041900; http://dx.doi.org/10.1128/AAC.01596-13
59. Cao Z, Zhang J, Niu YD, Cui N, Ma Y, Cao F, Jin L, Li Z, Xu Y. Isolation and Characterization of a “phiKMV-Like” Bacteriophage and Its Therapeutic Effect on Mink Hemorrhagic Pneumonia. PLoS One 2015; 10:e0116571; PMID:25615639; http://dx.doi.org/10.1371/journal.pone.0116571
60. Chhibber S, Kaur S, Kumari S. Therapeutic potential of bacteriophage in treating Klebsiella pneumoniae B5055-mediated lobar pneumonia in mice. J Med Microbiol 2008; 57:1508-13; PMID:19018021; http://dx.doi.org/10.1099/jmm.0.2008/002873-0
61. Singla S, Harjai K, Katare OP, Chhibber S. Bacteriophage-loaded nanostructured lipid carrier: Improved pharmacokinetics mediates effective resolution of Klebsiella pneumoniae induced lobar pneumonia. J Infect Dis 2015; PMID:25605867
62. Semler DD, Goudie AD, Finlay WH, Dennis JJ. Aerosol phage therapy efficacy in Burkholderia cepacia complex respiratory infections. Antimicrob Agents Chemother 2014; 58:4005-13; PMID:24798268; http://dx.doi.org/10.1128/AAC.02388-13
63. Smith HW, Huggins MB. Effectiveness of phages in treating experimental Escherichia coli diarrhoea in calves, piglets and lambs. J Gen Microbiol 1983; 129:2659-75; PMID:6355391
64. Hyman P, Abedon ST. Practical methods for determining phage growth parameters. Meth Mol Biol 2009; 501:175-202; PMID:19066822; http://dx.doi.org/10.1007/978-1-60327-164-6_18
65. Abedon ST. Lysis and the interaction between free phages and infected cells. In: Karam JD, Kutter E, Carlson K, Guttman B, eds. The Molecular Biology of Bacteriophage T4. Washington, DC: ASM Press, 1994:397-405.
66. Abedon ST. Bacteriophage T4 resistance to lysis-inhibition collapse. Genet Res 1999; 74:1-11; PMID:10505404; http://dx.doi.org/10.1017/S00166-72399003833
67. Bull JJ, Otto G, Molineux IJ. In vivo growth rates are poorly correlated with phage therapy success in a mouse infection model. Antimicrob Agents Chemother 2012; 56:949-54; PMID:22106213; http://dx.doi.org/10.1128/AAC.05842-11
68. Bull JJ, Gill JJ. The habits of highly effective phages: population dynamics as a framework for identifying therapeutic phages. Front Microbiol 2014; 5:618; PMID:25477869; http://dx.doi.org/10.3389/fmicb. 2014.00618
69. Lindberg HM, McKean KA, Wang I-N. Phage fitness may help predict phage therapy efficacy. Bacteriophage 2014; 4:e964081; http://dx.doi.org/10.4161/21597073.2014.964081
70. Henry M, Bobay LM, Chevallereau A, Saussereau E, Ceyssens PJ, Debarbieux L. The search for therapeutic bacteriophages uncovers one new subfamily and two new genera of pseudomonas-infecting myoviridae. PLoS One 2015; 10:e0117163; PMID:25629728; http://dx.doi.org/10.1371/journal.pone.0117163
71. Kutter EM, Kuhl S, Abedon ST. Reestablishing a place for phage therapy in western medicine. Future Microbiology 2015; http://dx.doi.org/10.2217/FMB.15.28